Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.
Hida, Tomoyuki
Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. [electronic resource] - Journal of thoracic imaging Mar 2020 - 101-107 p. digital
Publication Type: Journal Article
1536-0237
10.1097/RTI.0000000000000413 doi
Adult
Aged
Aged, 80 and over
Anaplastic Lymphoma Kinase--drug effects
Antineoplastic Agents--therapeutic use
Carcinoma, Non-Small-Cell Lung--diagnostic imaging
Crizotinib--therapeutic use
Female
Humans
Lung--diagnostic imaging
Lung Neoplasms--diagnostic imaging
Male
Middle Aged
Survival Analysis
Tomography, X-Ray Computed
Treatment Outcome
Tumor Burden
Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. [electronic resource] - Journal of thoracic imaging Mar 2020 - 101-107 p. digital
Publication Type: Journal Article
1536-0237
10.1097/RTI.0000000000000413 doi
Adult
Aged
Aged, 80 and over
Anaplastic Lymphoma Kinase--drug effects
Antineoplastic Agents--therapeutic use
Carcinoma, Non-Small-Cell Lung--diagnostic imaging
Crizotinib--therapeutic use
Female
Humans
Lung--diagnostic imaging
Lung Neoplasms--diagnostic imaging
Male
Middle Aged
Survival Analysis
Tomography, X-Ray Computed
Treatment Outcome
Tumor Burden